BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics total assets
Total assets on the balance sheet at the end of each period.
BrainStorm Cell Therapeutics's total assets was $788.00K at Jun 30, 2026. For fiscal 2025 it was $1.02M, down 44.2% from the year before. Over ten years it grew -24.5% a year on average. The highest annual figure on record is $51.26M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02M | -44.2% |
| FY2024 | Dec 31, 2024 | $1.83M | -56.5% |
| FY2023 | Dec 31, 2023 | $4.21M | -50.2% |
| FY2022 | Dec 31, 2022 | $8.45M | -71.1% |
| FY2021 | Dec 31, 2021 | $29.28M | -42.9% |
| FY2020 | Dec 31, 2020 | $51.26M | +684.5% |
| FY2019 | Dec 31, 2019 | $6.53M | -41.8% |
| FY2018 | Dec 31, 2018 | $11.23M | -1.7% |
| FY2017 | Dec 31, 2017 | $11.42M | +6.1% |
| FY2016 | Dec 31, 2016 | $10.77M | -37.0% |
| FY2015 | Dec 31, 2015 | $17.08M | +72.3% |
| FY2014 | Dec 31, 2014 | $9.91M | +109.7% |
| FY2013 | Dec 31, 2013 | $4.73M | -8.0% |
| FY2012 | Dec 31, 2012 | $5.14M | +87.2% |
| FY2011 | Dec 31, 2011 | $2.74M | +152.0% |
| FY2010 | Dec 31, 2010 | $1.09M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $788.00K | -69.3% |
| Q1 FY2026 | Mar 31, 2026 | $755.00K | -78.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.02M | -44.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.38M | -31.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.57M | -54.8% |
| Q1 FY2025 | Mar 31, 2025 | $3.57M | +6.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.83M | -56.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.03M | -64.4% |
| Q2 FY2024 | Jun 30, 2024 | $5.68M | -1.1% |
| Q1 FY2024 | Mar 31, 2024 | $3.35M | -57.5% |
| Q4 FY2023 | Dec 31, 2023 | $4.21M | -50.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.68M | -57.1% |
| Q2 FY2023 | Jun 30, 2023 | $5.75M | -69.7% |
| Q1 FY2023 | Mar 31, 2023 | $7.87M | -69.5% |
| Q4 FY2022 | Dec 31, 2022 | $8.45M | -71.1% |
| Q3 FY2022 | Sep 30, 2022 | $13.25M | -61.6% |
| Q2 FY2022 | Jun 30, 2022 | $18.96M | -55.1% |
| Q1 FY2022 | Mar 31, 2022 | $25.79M | -46.9% |
| Q4 FY2021 | Dec 31, 2021 | $29.28M | -42.9% |
| Q3 FY2021 | Sep 30, 2021 | $34.54M | +5.6% |
| Q2 FY2021 | Jun 30, 2021 | $42.24M | +119.7% |
| Q1 FY2021 | Mar 31, 2021 | $48.57M | +168.8% |
| Q4 FY2020 | Dec 31, 2020 | $51.26M | +684.5% |
| Q3 FY2020 | Sep 30, 2020 | $32.69M | +318.5% |
| Q2 FY2020 | Jun 30, 2020 | $19.22M | +116.8% |
| Q1 FY2020 | Mar 31, 2020 | $18.07M | +52.5% |
| Q4 FY2019 | Dec 31, 2019 | $6.53M | -41.8% |
| Q3 FY2019 | Sep 30, 2019 | $7.81M | -43.3% |
| Q2 FY2019 | Jun 30, 2019 | $8.86M | -57.8% |
| Q1 FY2019 | Mar 31, 2019 | $11.85M | +25.9% |
| Q4 FY2018 | Dec 31, 2018 | $11.23M | -1.7% |
| Q3 FY2018 | Sep 30, 2018 | $13.77M | +21.5% |
| Q2 FY2018 | Jun 30, 2018 | $21.02M | +162.7% |
| Q1 FY2018 | Mar 31, 2018 | $9.41M | +4.2% |
| Q4 FY2017 | Dec 31, 2017 | $11.42M | +6.1% |
| Q3 FY2017 | Sep 30, 2017 | $11.34M | -3.3% |
| Q2 FY2017 | Jun 30, 2017 | $8.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.77M | – |
| Q3 FY2016 | Sep 30, 2016 | $11.72M | – |
See a number that looks wrong?